Crystal Muilenburg - Evolus President
| EOLS Stock | USD 13.03 0.22 1.66% |
President
Ms. Crystal Muilenburg is Vice President, Corporationrationrate Communications and Public Relations of the company. Crystal has nearly two decades of experience in corporate communications, public relations, advocacy, society relations, strategic marketing and commercial marketing for midcap and startup enterprises. Most recently, Crystal was head of global strategic marketing at Sienna Biopharmaceuticals, a clinicalstage medical dermatology company, where she also supported the company corporate branding and corporate communications activities. Prior to Sienna, Crystal spent more than a decade at Allergan serving in various leadership positions in corporate communications and public relations and U.S. and international marketing, specifically in medical aesthetics, where she built a deep expertise in brand awareness and consumer activation strategies while marketing directly to women and influencers. Crystal earned a B.S. degree in Biology from California Polytechnic State University, San Luis Obispo. since 2019.
| Age | 44 |
| Tenure | 6 years |
| Address | 520 Newport Center Drive, Newport Beach, CA, United States, 92660 |
| Phone | 949 284 4555 |
| Web | https://www.evolus.com |
Evolus Management Efficiency
The company has return on total asset (ROA) of (0.0808) % which means that it has lost $0.0808 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.6168) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.21 in 2025. At this time, Evolus' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 6.3 M in 2025, whereas Net Tangible Assets are likely to drop (62 M) in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Mark Neumann | Intracellular Th | 61 | |
| Marcela Pagano | Procaps Group SA | 58 | |
| Luis Aragon | Procaps Group SA | 61 | |
| Mauricio Caballero | Procaps Group SA | 48 | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Michael Landine | Alkermes Plc | 70 | |
| David Gaffin | Alkermes Plc | 52 | |
| Robert Davis | Intracellular Th | 74 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Rob Aukerman | Phibro Animal Health | 67 | |
| Jack MBA | Supernus Pharmaceuticals | 64 | |
| Stephen Carey | ANI Pharmaceuticals | 54 | |
| Samson Li | Phibro Animal Health | 53 | |
| Lisa Escudero | Phibro Animal Health | 63 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| Jonathan Bendheim | Phibro Animal Health | 49 | |
Management Performance
| Return On Equity | -8.62 | ||||
| Return On Asset | -0.0808 |
Evolus Inc Leadership Team
Elected by the shareholders, the Evolus' board of directors comprises two types of representatives: Evolus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolus. The board's role is to monitor Evolus' management team and ensure that shareholders' interests are well served. Evolus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Crystal Muilenburg, Vice President Corporate Communications and Public Relations | ||
| Jessica Novak, Senior Resources | ||
| Tomoko YamagishiDressler, Chief Officer | ||
| CCFP DipSportMed, Chief RD | ||
| David Erickson, VP Relations | ||
| David Moatazedi, President CEO, Director | ||
| Kurt Knab, Vice President of Sales | ||
| Sandra Beaver, Chief Officer | ||
| Jeffrey Plumer, General Counsel | ||
| Nareg Sagherian, Head Communications |
Evolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.62 | ||||
| Return On Asset | -0.0808 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.01) % | ||||
| Current Valuation | 871.24 M | ||||
| Shares Outstanding | 63.59 M | ||||
| Shares Owned By Insiders | 10.59 % | ||||
| Shares Owned By Institutions | 82.62 % | ||||
| Number Of Shares Shorted | 6.56 M | ||||
| Price To Earning | (5.55) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.